Parenteral Manual

Eribulin (INVESTIGATIONAL)

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
HALAVEN, IND #122686,E7389
Classification: 
Antineoplastic - CYTOTOXIC
Original Date: 
September 2014
Indications: 
  • Children:  Investigational in children greater than or equal to 12 years of age for recurrent or refractory osteosarcoma
  • Adults:  Approved for use in metastatic breast cancer
Reconstitution and Stability: 
  • single-use vial containing 0.5 mg/mL (1 mg in 2 mL vial);  clear, colourless solution
  • store in original container at room temperature
  • undiluted drug is stable in a polypropylene syringe for 4 hours at room temperature and 24 hours in the refrigerator
  • concentrations between 0.005 mg/mL and 0.2 mg/mL in 0.9% sodium chloride stable in syringe or polypropylene/polyethylene bags for 48 hous at room temperature or in the refrigerator
Compatibility: 
  • 0.9% sodium chloride ONLY
  • DO NOT mix with any other drugs
  • INCOMPATIBLE with Dextrose
Administration: 

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC NO
IM NO
IV Direct YES - over 2 to 5 minutes
IV Intermittent Infusion NO
IV Continuous Infusion NO
Dosage: 

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

Children:  (greater than or equal to 12 years of age):  1.4 mg/m2 IV days 1 and 8 of each 21 day cycle; refer to protocol for any dose modifications

Adult:  same as above

Dose adjustment required for liver and kidney impairment.  Refer to specific protocol and standard references

Potential hazards of parenteral administration: 

Extravasation risk:  not a vesicant

Immediate  (within a few minutes or hours):
-  nausea, vomiting (low emetogenicity), hypersensitivity

Early  (within a few days or weeks, prior to next cycle):
-  likely (greater than 20%) - neutropenia, thrombocytopenis, anemia, alopecia, fatigue, constipation, weight loss, transaminitis
-  less likely ( less than or equal to 20%) - abnormal electrolytes, abdominal pain, diarrhea, dry mouth, fever, headache, mucositis, myalgia, periperal motor and/or sensory neuropathy, prolonged QTc interval

Treatment for unusual side effects are available through the study chair identified on the front page of the protocol and/or pharmacy

Notes: 
  • extensively metabolized by CYP 3A4 but does not significantly inhibit or induce CYP 3A4 activity.  No drug - drug interactions are expected with CYP 3A4 inhibitors or inducers
  • CONTRAINDICATIONS -
    -  hypersensitivity to Eribulin or any of its excipients;  concurrent serious or uncontrolled infection
    -  medications that prolong QTc interval are prohibited ( e.g. macrolide anibiotics, domperidone, pentamidine, phenothiazines);  if possible, avoid medications that may prolong QTc (e.g. ondansetron, granisetron, some quinolones, voriconazole, famotidine)
References: 

Children's Oncology Group protocol AOST1322 (August 12, 2014 version)

Eribulin Monograph, Cancer Care Ontario website:  accessed September 25, 2014

Eribulin Monograph, Lexi-Comp on-line, accessed September 25, 2014

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.